Metabotropic G-protein-coupled glutamate receptors as therapeutic targets

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 433-440

  Pellicciari, Roberta ^a   Costantino, Gabriele ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; METABOTROPIC RECEPTOR;

BRAIN DISEASE; CHEMISTRY; HUMAN; ISCHEMIA; MOLECULAR BIOLOGY; NONHUMAN; PHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; THERAPY;

EID: 0033178258     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80064-7     Document Type: Article

References (50)

1. Conn PJ, Pin JP: Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
2. Parmentier ML, Pin J-P, Bockaert J, Grau Y: Cloning and functional expression of a Drosophila metabotropic glutamate receptor expressed in the embryonic CNS. J Neurosci 1996, 16:6687-6694.
3. Albani Torregrossa S, Attucci S, Marinozzi M, Pellicciari R, Moroni F, Pellegrini-Giampietro DE: Antagonist pharmacology of metabotropic glutamate receptors coupled to phospholipase D activation in adult rat hippocampus: Focus on (2R,1′S,2′R,3′S)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine versus 2,3-dihydroxyphenylglycine. Mol Pharmacol 1999, 55:699-707. The pharmacology of a new class of phospholipase D (PLD)-coupled metabotropic glutamate receptors is described. PCCG-13, a new potent, selective and competitive antagonist, the first so far described, is pharmacologically characterized and will allow a better understanding of the role played by the novel class of PLD-coupled receptors.
4. Boss VK, Conn PJ: Metabotropic excitatory amino acid receptor activation stimulates phospholipase D in hippocampal slices. J Neurochem 1992, 59:2340-2343.
5. Boss VK, Nutt M, Conn PJ: ⌊-Cysteine sulfinic acid as an endogenous agonist of a novel metabotropic receptor coupled to phospholipase D activity. Mol Pharmacol 1994, 45:1177-1182.
6. Klein J, Vakil M, Bergman F, Holler T, Iovino M, Löffelholz K: Glutamatergic activation of hippocampal phospholipase D: Postnatal fading and receptor desensitization. J Neurochem 1998, 70:1679-1685.
7. Romano C, Yang WL, O'Malley K: Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 1996, 271:28612-28616.
8. O'Hara PJ, Sheppard PO, Thogersen H, Venezia D, Haldeman BA, McGrane V, Houamed KM, Thomsen C, Gilbert TL, Mulvihill ER: The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 1993, 11:41-52.
9. Okamoto T, Sekiyama N, Otsu M, Shimada Y, Sato A, Nakanishi S, Jingami H: Expression and purification of the extracellular ligand binding region of metabotropic glutamate receptor subtype 1. J Biol Chem 1998, 273:13089-13096. A soluble form of the amino-terminal domain of metabotropic glutamate receptor subtype 1 is expressed, purified and shown to retain the binding characteristic of native receptors. This observation demonstrates that the binding event can occur outside the membrane environment and permits anticipation of a future crystallization of the amino-terminal domain.
10. B receptors, this paper offers very interesting consideration on structural aspects and binding mechanisms of type 3 G-protein-coupled receptor superfamily, including glutamate metabotropic receptors.
11. Costantino G, Pellicciari R: Homology modeling of metabotropic glutamate receptors (mGluRs). Structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists. J Med Chem 1996, 39:3998-4006.
12. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T: Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders? Trends Neurosci 1996, 19:267-271.
13. Eaton SA, Jane DE, Jones PL, Porter RH, Pook PC, Sunter DC, Udvarhelyi PM, Roberts PJ, Salt TE, Watkins JC: Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine. Eur J Pharmacol 1993, 244:195-197.
14. Pellicciari R, Luneia R, Costantino G, Marinozzi M, Natalini B, Jakobsen P, Kanstrup A, Lombardi G, Moroni F, Thomsen C: 1-Aminoindan-1,5-dicarboxylic acid: A novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J Med Chem 1995, 38:3717-3719.
15. Pellicciari R, Raimondo M, Marinozzi M, Natalini B, Costantino G, Thomsen C: (S)-(+)-2-(3′-carboxybicyclo[1.1.1]pentyl)-glycine, a structurally new group I metabotropic glutamate receptor antagonist. J Med Chem 1996, 39:2874-2876.
16. Clark BP, Baker SR, Goldswothy J, Harris JR, Kingston AE: (+)-2 Methyl-4-carboxyphenylglycine (LY367385) selectively antagonises metabotropic glutamate receptors. Bioorg Med Chem Lett 1997, 7:2777-2780.
17. Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE: (RS)-2-chloro-5 hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 1997, 36:265-267.
18. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prezeau L, Pin JP, Thomsen C, Kuhn R: CPCOOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 1999, 55:453-461. This paper is the first to describe the possibility of modulating mGluR1 through noncompetitive antagonists.
19. Annoura H, Fukunaga A, Uesugi M, Tatsuoka T, Horikawa Y: A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg Med Chem Lett 1996, 6:763-767.
20. Gasparini F, Lingenheokl K, Flor PJ, Munier N, Heinrich M, Pagano A, Vranesic I, Biollaz M, Heckendorn R, Allgeier H et al.: Methylphenylethynylpiperldine (MPEP): A novel potent subtype selective and systemically active antagonist at metabotropic glutamate receptor subtype 5. Br J Pharmacol 1999, in press. This paper describes a new, potent and systemically active noncompetitive metabotropic glutamate receptor subtype 5 antagonist, the first so far reported, and highlights its anti-hyperalgesic activities.
21. Pellegrini-Giampietro DE, Cozzi A, Peruginelli F, Leonardi P, Meli E, Pellicciari R, Moroni F: AIDA and S-CBPG, two mGlu1 receptor-preferring antagonists reduce neuronal death and in vivo models of cerebral ischemia. Eur J Neurosci 1999, in press. This paper points out the role of metabotropic glutamate receptor subtype 1 antagonist receptors in the pathological mechanisms responsible for the postischemic neuronal death.
22. Moroni F, Cozzi A, Lombardi G, Sourtcheva S, Leonardi P, Carfi M, Pellicciari R: Presynaptic mGlu1 type receptors potentiate transmitter output in the rat cortex. Eur J Pharmacol 1998, 347:189-195.
23. Fisher K, Coderre TJ: Hyperalgesia and allodynia induced by intrathecal (RS)-dihydroxyphenylglycine in rats. Neuroreport 1998, 9:1169-1172.
24. Moroni F, Lombardi G, Thomsen C, Leonardi P, Attucci S, Peruginelli F, Torregrossa SA, Pellegrini-Giampietro DE, Luneia R, Pellicciari R: Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. J Pharmacol Exp Ther 1997, 281:721-729.
25. Zahn PK, Brennan TJ: Intrathecal metabotropic glutamate receptor antagonists do not decrease mechanical hyperalgesia in a rat model of post-operative pain. Anesth Analg 1998, 87:1354-1359.
26. Pellicciari R, Marinozzi M, Natalini B, Costantino G, Luneia R, Giorgi G, Moroni F, Thomsen C: Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(2′-carboxy-3′-phenylcyclopropyl)glycine. Focus on (2S,1′S,2′S,3′R)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors antagonist. Med Chem 1996, 39:2259-2269.
27. Kozikowski AP, Steensma D, Araldi GL, Tuckmantel W, Wang S, Pshenichkin S, Surina E, Wroblewski JT: Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-l, a potent mGluR agonist. J Med Chem 1998, 41:1641-1650. The synthesis and the biological evaluation of a new conformationally constrained ⌊-glutamate analog, eqiupotent as a metabotropic glutamate receptor subtype 1 and 2 agonist, is reported. Very interesting structure/activity relationships are shown.
28. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL et al.: Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997, 40:528-537.
29. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL Jr, Wright RA, Johnson BG et al.: Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic ammo acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999, 42:1027-1040.
30. Ornstein PL, Bleisch TJ, Arnold MB, Wright RA, Johnson BG, Schoepp DD: 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-y)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution. J Med Chem 1998, 41:346-357.
31. Wroblewska B, Wroblewski JT, Saab OH, Neale JH: N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. J Neurochem 1993, 61:943-948.
32. Wroblewska B, Santi MR, Neale JH: N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 1998, 24:172-179.
33. Cozzi A, Attucci S, Peruginelli F, Marinozzi M, Luneia R, Pellicciari R, Moroni F: Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: In vivo studies with (2S,1′S,2′S,3′R)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine, a new potent and selective antagonist. Eur J Neurosci 1997, 9:1350-1355.
34. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ: Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998, 284:651-660.
35. Moghaddam B, Adams BW: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352. The therapeutic potential of group II agonists in the treatment of psychiatric disorders such as schizophrenia is described in this paper. LY354740 is shown to reverse the effect of phenyciclidine in rats, a common experimental model for epilepsy.
36. Monn JA, Valli MJ, Johnson BG, Salhoff CR, Wright RA, Howe T, Bond A, Lodge D, Spangle LA, Paschal JW et al.: Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: Identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. J Med Chem 1996, 39:2990-3000.
37. Battaglia G, Bruno V, Ngomba RT, Di Grezia R, Copani A, Nicoletti F: Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. Eur J Pharmacol 1998, 356:271-274.
38. Bond A, O'Neill MJ, Hicks CA, Monn JA, Lodge D: Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport 1998, 9:1191-1193.
39. Lam AG, Soriano MA, Monn JA, Schoepp DD, Lodge D, McCulloch J: Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia. Neurosci Lett 1998, 254:121-123.
40. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F: Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 1998, 18:9594-9600. An interesting mechanism for group-II-mediated neuroprotection after excitotoxic insult is proposed and involves the group II agonist-mediated release of neurotrophic factors.
41. Toms NJ, Jane DE, Kemp MC, Bedingfield JS, Roberts PJ: The effects of (RS)-alpha cyclopropyl-4-phosphonophenylglycine ([RS])-CPPG), a potent and selective metabotropic glutamate receptor antagonist. Br J Pharmacol 119:851-854.
42. Flor PJ: Neuroprotection in vitro and in vivo by (R,S)-PPG, a potent and selective group III metabotropic glutamate receptor antagonist. Soc Neurosci Abstr 24:431.11.
43. Ahmadian H, Nielsen B, Brauner-Osborne H, Johansen TN, Stensbol TB, Slok FA, Sekiyama N, Nakanishi S, Krogsgaard-Larsen P, Madsen U: (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. J Med Chem 1997, 40:3700-3705.
44. Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR Jr, Johnson BG, Schoepp DD, Belagaje RM: Group III human metabotropic glutamate receptors 4, 7 and 8: Molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res 1998, 53:88-97. The molecular cloning, expression and an interesting pharmacological comparison of three subtypes of group III mGluRs are presented.
45. Gerlai R, Roder JC, Hampson DR: Altered spatial learning and memory in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. Behav Neurosci 1998, 112:525-532.
46. Holler TE, Cappel E, Klein J, Löffelholz K:. Glutamate activates phospholipase D in hippocampal slices of newborn and adult rats. J Neurochem 1993, 61:1569-1572.
47. Pellegrini-Giampietro DE, Albani Torregrossa S, Moroni F: Pharmacological characterization of metabotropic glutamate receptors coupled to phospholipase D in the rat hippocampus. Br J Pharmacol 1996, 118:1035-1043.
48. Exton JH: Phospholipase D: Enzymology, mechanisms of regulation, and function. Physiol Rev 1997, 77:303-320.
49. 2+ signal transduction. J Biol Chem 1992, 267:13361-13368.
50. Pellicciari R, Marinozzi M, Costantino G, Natalini B, Pellegrini-Giampietro DE, Moroni F: (2R,1′S,2′R,3′S)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine (PCCG-13), the first potent and selective competitive antagonist of PLD-coupled metabotropic glutamate receptors, asymmetric synthesis and preliminary biological properties. J Med Chem 1999, in press.